U.S. markets closed

Ginkgo Bioworks Holdings, Inc. (DNA)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
2.8500-0.4000 (-12.31%)
At close: 04:00PM EDT
2.8700 +0.02 (+0.70%)
After hours: 04:35PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close3.2500
Bid2.8500 x 36900
Ask2.8900 x 29200
Day's Range2.7900 - 3.1700
52 Week Range2.0900 - 15.8640
Avg. Volume25,975,159
Market Cap5.087B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.6720
Earnings DateAug 15, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.98
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for DNA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Ginkgo Bioworks Holdings, Inc.
    Analyst Report: Stem, Inc.Stem is a is provider of energy storage systems. The company bundles third-party hardware with its proprietary Athena software to provide customers a turnkey solution. Stem sells its solutions to commercial and industrial customers as well as independent power producers and renewable developers. Its solutions help customers maximize renewable energy generation and help build a cleaner and more resilient grid. In early 2022, the company acquired AlsoEnergy, a provider of solar asset management software.
    Fair Value
    Economic Moat
    7 days agoMorningstar
View more
  • PR Newswire

    Ginkgo Bioworks Announces Strategic Purchase of Epidemiological Data Infrastructure Assets

    Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced the purchase of certain epidemiological data infrastructure assets from Baktus, Inc., a Delaware-based public benefit corporation. Under the terms of the deal, Ginkgo will assume ownership of proprietary datasets, modeling and analytic tools, and a software platform with the capabilities to track, model, and forecast epidemics and associated risks and impacts. Ginkgo also expects to integrate sever

  • PR Newswire

    Ginkgo Bioworks Reports Second Quarter 2022 Financial Results

    Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) ("Ginkgo"), the leading horizontal platform for cell programming, today announced its results for the second quarter ended June 30, 2022. The update, including a webcast slide presentation with additional details on the second quarter and supplemental financial information, will be available at

  • GlobeNewswire

    Ginkgo Bioworks and XpresCheck Receive Award to Expand CDC’s Traveler-Based SARS-CoV-2 Genomic Surveillance Program In U.S. Airports

    Public-private partnership to enable the development of innovative, sustainable infrastructure designed to set the global standard for travel biosecurityBOSTON and NEW YORK, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Ginkgo Bioworks (NYSE: DNA) and XpresSpa Group, Inc. (Nasdaq: XSPA) announced they will continue to support the Centers for Disease Control and Prevention’s (CDC’s) traveler-based SARS-CoV-2 genomic surveillance program through a new contract awarded August 12, 2022. The partnership is expec